Previous close | 213.70 |
Open | 217.40 |
Bid | 219.30 x 0 |
Ask | 219.00 x 0 |
Day's range | 216.60 - 219.20 |
52-week range | 213.00 - 293.50 |
Volume | |
Avg. volume | 204,831 |
Market cap | 174.347B |
Beta (5Y monthly) | 0.15 |
PE ratio (TTM) | 15.30 |
EPS (TTM) | 14.31 |
Earnings date | 25 Jul 2024 |
Forward dividend & yield | 9.60 (4.42%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Sarepta (SRPT) reports better-than-expected Q1 earnings on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Q1 2024 Sarepta Therapeutics Inc Earnings Call
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.